RUBY - Rubius Therapeutics, Inc.
| Previous Close | 10.18 |
| Open | 10.13 |
| Bid | 9.56 x 1200 |
| Ask | 9.59 x 800 |
| Day's Range | 9.55 - 10.33 |
| 52 Week Range | 9.55 - 26.29 |
| Volume | 120,228 |
| Avg. Volume | 229,626 |
| Market Cap | 764.653M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.33 |
- GlobeNewswire
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End CAMBRIDGE, Mass., Aug. 13, 2019 -- Rubius Therapeutics, Inc..
- GlobeNewswire
Rubius Therapeutics to Announce Second Quarter 2019 Financial Results
CAMBRIDGE, Mass., Aug. 07, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.
- GlobeNewswire
Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy
Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Kris Elverum as senior vice president of business development and strategy. In his role, Kris will be responsible for developing the Company’s corporate strategy and creating and executing new business development opportunities. “As we continue to advance our promising pipeline of Red Cell Therapeutics™ for the potential treatment of rare diseases, cancer and autoimmune diseases, our corporate growth strategy is a crucial part of bringing our new treatment options to patients worldwide,” said Pablo J. Cagnoni, M.D., chief executive officer.
- Simply Wall St.
Investors Who Bought Rubius Therapeutics (NASDAQ:RUBY) Shares A Year Ago Are Now Down 44%
The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...
- GlobeNewswire
Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs
Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of allogeneic, off-the-shelf cellular medicines, today announced the issuance of three patents from the U.S. Patent and Trademark Office (USPTO) related to its rare disease and oncology programs and platforms. The third patent, the Company’s first issued composition of matter patent in immuno-oncology, relates to human cells having a checkpoint inhibitor linked to the cell surface. In total, Rubius Therapeutics has 29 patent families and more than 125 pending patent applications worldwide.
- GlobeNewswire
Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference
CAMBRIDGE, Mass., May 28, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.
- American City Business Journals
Preclinical biotech Stoke Therapeutics plans $86M IPO
An RNA-altering startup led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products is hoping to raise $86 million in an IPO, it disclosed Thursday.
- GlobeNewswire
Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019 Company Announces.
- American City Business Journals
In slow year for life science IPOs, this venture firm is making big money
The slowing of Massachusetts biotech and medical device companies’ stock market launches has left most venture creation firms without exit opportunities, except for one.
- GlobeNewswire
Rubius Therapeutics to Announce First Quarter 2019 Financial Results
CAMBRIDGE, Mass., May 06, 2019 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.
- GlobeNewswire
Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit
CAMBRIDGE, Mass., April 03, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.
- GlobeNewswire
Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., April 02, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.
- GlobeNewswire
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates
Investigational New Drug Application Cleared for First-Ever Red Cell Therapeutic™, RTX-134, for Treatment of Phenylketonuria Data from Company’s Oncology Pipeline to be.
- Simply Wall St.
How Many Insiders Bought Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is not uncommon to see companies perform well inRead More...
- GlobeNewswire
Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer
Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Natalie Holles, president and chief operating officer of Audentes Therapeutics, as a member of the company’s board of directors and Greg Whitehead as senior vice president and chief quality officer. Rubius further announced that Roger Pomerantz, M.D., who has served as a board member since Rubius’ founding, has decided not to stand for reelection with his board membership ending by June 2019.
- GlobeNewswire
Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results
CAMBRIDGE, Mass., March 19, 2019 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.
- GlobeNewswire
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
Rubius Therapeutics, Inc. (RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for RTX-134, an allogeneic, off-the-shelf cellular therapy for the potential treatment of patients with phenylketonuria (PKU). The Phase 1b clinical trial is expected to be the first-ever clinical investigation of genetically engineered red blood cells.
- GlobeNewswire
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., Feb. 27, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an.
- GlobeNewswire
Rubius Therapeutics to Participate at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 19, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an.
- GlobeNewswire
Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics, Inc. (RUBY), a biotechnology company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced anticipated 2019 development milestones. Pablo J. Cagnoni, M.D., chief executive officer, will present these updates and review 2018 accomplishments today at 9:00 a.m. PT at the 37th Annual J.P. Morgan Healthcare Conference. “At Rubius Therapeutics, we made tremendous progress in 2018, transforming from a privately-held company into a publicly-traded, fully integrated research and development organization that is advancing a robust pipeline of Red Cell Therapeutics™ for the potential treatment of rare enzyme deficiencies, cancer and autoimmune diseases,” said Dr. Cagnoni.
- GlobeNewswire
Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 27, 2018 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies,.
- GlobeNewswire
Rubius Therapeutics, Inc. Secures $75 Million Loan Facility
Rubius Therapeutics, Inc. (RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today announced it has entered into a loan and security agreement with Solar Capital Partners and its affiliates for a term loan of up to $75.0 million to be funded in three tranches of $25.0 million each. The proceeds will be used to advance its pipeline of Red Cell Therapeutics™ and for general corporate purposes, further extending the Company’s cash runway into 2021. “This flexible, non-dilutive financing strengthens our financial position and supports our key therapeutic programs advancing towards clinical trials,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics.
- GlobeNewswire
Rubius Therapeutics Added to Nasdaq Biotechnology Index
CAMBRIDGE, Mass., Dec. 17, 2018 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, today.
- Bloomberg
Qatar Fund Building Venture Capital Unit for U.S. Startups
The Qatar Investment Authority, created to handle the windfall from the country’s gas and oil exports, has invested in companies including Foursquare Labs Inc., biotech firm Rubius Therapeutics Inc., Homology Medicines Inc., Thoughtspot Inc. and Grail Inc., said the people, asking not to be identified because the deals are private.
